Arcutis Biotherapeutics Inc (NASDAQ:ARQT) has a beta value of 1.66 and has seen 0.47 million shares traded in the recent trading session. The company, currently valued at $1.83B, closed the recent trade at $15.45 per share which meant it lost -$0.28 on the day or -1.75% during that session. The ARQT stock price is -14.89% off its 52-week high price of $17.75 and 54.76% above the 52-week low of $6.99. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.0 million shares traded. The 3-month trading volume is 2.31 million shares.
The consensus among analysts is that Arcutis Biotherapeutics Inc (ARQT) is Buy stock at the moment, with a recommendation rating of 1.25. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.21.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Sporting -1.75% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ARQT stock price touched $15.45 or saw a rise of 12.96%. Year-to-date, Arcutis Biotherapeutics Inc shares have moved 10.95%, while the 5-day performance has seen it change -10.61%. Over the past 30 days, the shares of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) have changed 12.89%. Short interest in the company has seen 15.11 million shares shorted with days to cover at 6.95.
Wall Street analysts have a consensus price target for the stock at $19, which means that the shares’ value could jump 18.68% from the levels at last check today.. The projected low price target is $19.0 while the price target rests at a high of $19.0. In that case, then, we find that the latest price level in today’s session is -22.98% off the targeted high while a plunge would see the stock gain -22.98% from the levels at last check today..
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
The company’s shares have gained 68.72% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 53.55%.
6 analysts offering their estimates for the company have set an average revenue estimate of 64.1M for the current quarter. 6 have an estimated revenue figure of 72.63M for the next ending quarter. Year-ago sales stood 49.57M and 30.86M respectively for this quarter and the next, and analysts expect sales will grow by 29.32% for the current quarter and 53.55% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -0.98% over the past 5 years.
ARQT Dividends
Arcutis Biotherapeutics Inc is expected to release its next earnings report on 2025-Feb-24 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
Insiders own 2.02% of the company shares, while shares held by institutions stand at 112.07% with a share float percentage of 114.38%. Investors are also buoyed by the number of investors in a company, with Arcutis Biotherapeutics Inc having a total of 288.0 institutions that hold shares in the company. The top two institutional holders are JENNISON ASSOCIATES LLC with over 11.57 million shares worth more than $107.62 million. As of 2024-06-30, JENNISON ASSOCIATES LLC held 9.3712% of shares outstanding.
The other major institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, with the holding of over 10.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $93.04 million and represent 8.1021% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. . As of Dec 31, 2024 , the former fund manager holds about 2.72% shares in the company for having 3.23 shares of worth $50.03 million while later fund manager owns 3.09 shares of worth $47.82 million as of Feb 28, 2025 , which makes it owner of about 2.60% of company’s outstanding stock.
